title: Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings.
abstract: Linezolid is a new antimicrobial agent effective against drug-resistant gram-positive pathogens which are common causes of infections in hospitalized patients. Many such patients rely on the intravenous or enteral route for nutrition and drug administration. Therefore, the bioavailability of linezolid administered enterally in the presence of enteral feedings in hospitalized patients was examined. Eighteen subjects were assessed in a randomized single-dose crossover study; 12 received continuous enteral feedings, while 6 did not (controls). Both groups received linezolid 600 mg intravenously and orally (control) or enterally, with the alternate route of administration separated by a 24-h washout period. Pharmacokinetic parameters derived from noncompartmental and compartmental analysis incorporating linear and nonlinear elimination pathways were compared between groups: F, Ka, Vs, K23, K32, Vmax, Km, and K20 (bioavailability, absorption rate constant, volume of central compartment normalized to body weight, intercompartmental rate constants, maximum velocity, Michaelis-Menten constant, and elimination rate constant, respectively). Pharmacokinetic (PK) data were available from 17 patients. The linezolid oral suspension was rapidly and completely absorbed by either the oral or enteral route of administration. Bioavailability was unaltered in the presence of enteral feedings. PK estimates remain similar regardless of the model applied. At the therapeutic dose used, only slight nonlinearity in elimination was observed. A linezolid oral suspension may be administered via the enteral route to hospitalized patients without compromise in its excellent bioavailability and rapid rate of absorption. Compartmental pharmacokinetic analysis offers a more flexible study application, since bioavailability (F) can be estimated directly with intermixed intravenous/oral doses without a need for a washout period.
authors.affiliation: School of Pharmacy, University of Southern California, Los Angeles, CA 90033, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Beringer
authors.forename: Megan
authors.initials: M
authors.lastname: Nguyen
authors.forename: Nils
authors.initials: N
authors.lastname: Hoem
authors.forename: Stan
authors.initials: S
authors.lastname: Louie
authors.forename: Mark
authors.initials: M
authors.lastname: Gill
authors.forename: Michael
authors.initials: M
authors.lastname: Gurevitch
authors.forename: Annie
authors.initials: A
authors.lastname: Wong-Beringer
mesh_terms: D000081:Acetamides / Q000493:pharmacokinetics*; D000368:Aged; D000890:Anti-Infective Agents / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004750:Enteral Nutrition; D005260:Female; D006207:Half-Life; D006801:Humans; D000069349:Linezolid; D008297:Male; D008875:Middle Aged; D017711:Nonlinear Dynamics; D023303:Oxazolidinones / Q000493:pharmacokinetics*; D011446:Prospective Studies
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid